Hyderabad: Hyderabad has emerged as a key hub in India’s first indigenous dengue vaccine development, with AIIMS Bibinagar at the forefront of the ongoing phase III clinical trials.
The All India Institute of Medical Sciences, Bibinagar, is among 20 sites nationwide involved in the final testing stage of the vaccine, dubbed ‘DengiAll’, developed by the Indian Council of Medical Research (ICMR) and Panacea Biotec.
According to trial officials, over 70% of the targeted 10,000 participants have been enrolled across India. Final recruitment is underway and expected to conclude by October. AIIMS Bibinagar’s study is being led by Dr Rashmi Kundapur, Additional Professor, Department of Community Medicine.
The vaccine under trial is tetravalent—designed to protect against all four circulating dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
The phase III program is expected to cost between ₹26 crore and ₹30 crore, and is seen as the final step before India rolls out its first homegrown single-dose dengue vaccine. The base vaccine strain was originally developed by the National Institutes of Health (NIH) in, United States.
